BridgeBio Pharma Inc’s filing revealed that its Director DANIELS RONALD J unloaded Company’s shares for reported $3.89 million on Nov 06 ’25. In the deal valued at $63.72 per share,61,031 shares were sold. As a result of this transaction, DANIELS RONALD J now holds 16,991 shares worth roughly $1.05 million.
Then, RONALD J DANIELS bought 61,031 shares, generating $3,888,999 in total proceeds.
Before that, MCCORMICK FRANK sold 198,359 shares. BridgeBio Pharma Inc shares valued at $13,206,528 were divested by the Director at a price of $66.58 per share. As a result of the transaction, MCCORMICK FRANK now holds 679,979 shares, worth roughly $42.02 million.
A number of analysts have revised their coverage, including Truist’s analysts, who began to cover the stock in late July with a ‘”a Buy”‘ rating. Jefferies began covering BBIO with “Buy” recommendation on July 14, 2025. Oppenheimer revised its rating on July 09, 2025. It rated BBIO as “an Outperform” which previously was an “a Perform”.
Price Performance Review of BBIO
On Friday, BridgeBio Pharma Inc [NASDAQ:BBIO] saw its stock fall -1.48% to $61.8. Over the last five days, the stock has lost -1.34%. BridgeBio Pharma Inc shares have risen nearly 142.16% since the year began. Nevertheless, the stocks have risen 125.22% over the past one year. While a 52-week high of $69.48 was reached on 10/29/25, a 52-week low of $21.72 was recorded on 01/02/25.
Levels Of Support And Resistance For BBIO Stock
The 24-hour chart illustrates a support level at 60.48, which if violated will result in even more drops to 59.16. On the upside, there is a resistance level at 63.19. A further resistance level may holdings at 64.58.
How much short interest is there in BridgeBio Pharma Inc?
A steep rise in short interest was recorded in BridgeBio Pharma Inc stocks on 2025-10-15, dropping by -2.09 million shares to a total of 17.35 million shares. Yahoo Finance data shows the prior-month short interest on 2025-09-15 was 19.44 million shares. There was a decline of -12.04%, which implies that there is a negative sentiment for the stock.
The most recent change occurred on June 17, 2025 when Wolfe Research began covering the stock and recommended ‘”an Outperform”‘ rating along with a $49 price target.
